OrganoDrug

OrganoDrug Solutions for Lung Fibrosis & IBD Drug Screening

Internal OrganoDrug Development Program Leveraging AI and Platform Technology

Leveraging AI and our platform technology, we are developing our internal drug program, with an initial focus on lung fibrosis and IBD.

At OrganoBiotech our team has developed a machine learning model capable of predicting the binding affinity of small molecules to defined targets.

Utilizing the model, we have virtually screened over 2,000 drug compounds and selected the top-ranked candidates for efficacy testing in our pulmonary fibrosis model.